{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:52Z","timestamp":1790079052296,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023\u20104\u201017"],"award-info":[{"award-number":["2023\u20104\u201017"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["24JRRA314"],"award-info":[{"award-number":["24JRRA314"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017956","name":"Health Commission of Gansu Province","doi-asserted-by":"publisher","award":["GSWSQN2024\u201010"],"award-info":[{"award-number":["GSWSQN2024\u201010"]}],"id":[{"id":"10.13039\/100017956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,11,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    While third\u2010generation EGFR tyrosine kinase inhibitors (TKIs) improve outcomes in EGFR\u2010mutant NSCLC, optimal selection between these agents remains uncertain. This real\u2010world study compares the efficacy and safety of aumolertinib with those of osimertinib in the first\u2010line treatment setting. We retrospectively analyzed 109 EGFR\u2010mutant (exon 19del\/L858R) NSCLC patients treated with first\u2010line aumolertinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200953) or osimertinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200956) across four tertiary hospitals (2016\u20132023). The primary end points included progression\u2010free survival (PFS) and safety; secondary end points encompassed overall survival (OS), objective response rate (ORR), and predictive biomarker identification through subgroup analyses. Aumolertinib demonstrated superior median PFS compared to osimertinib (34.4 vs. 26.9\u2009months; HR 0.52, 95% CI 0.29\u20130.92,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.031), with comparable OS (HR 0.76, 95% CI 0.27\u20132.15,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.60). No significant differences emerged in primary lesion ORR (33.96%, 18\/53 vs. 42.86%, 24\/56) or adverse event (AE) rates (37.7%, 20\/53 vs. 39.3%, 22\/56). Subgroup analyses confirmed enhanced PFS benefit with aumolertinib in exon 19del\u2010mutant (HR 0.43, 95% CI 0.21\u20130.87,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and co\u2010mutation\u2010negative (HR 0.53, 95% CI 0.25\u20131.14,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.08) populations. Subgroup analysis identified age &lt;\u200965\u2009years (HR 0.46, 95% CI 0.22\u20130.99,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.046), brain metastases (HR 0.24, 95% CI 0.09\u20130.66,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006), and exon 19del status (HR 0.43, 95% CI 0.2\u20130.89,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.023) as independent PFS predictors. Regarding safety, aumolertinib showed a lower overall incidence of liver dysfunction compared to osimertinib (9.43%, 5\/53 vs. 14.29%, 8\/56), with Grade \u2265\u20093 events being rare (1.89%, 1\/53). Given that liver function is a critical determinant of prognosis, the manageable hepatic safety profile of aumolertinib supports its long\u2010term clinical utility. Our study demonstrated a clinically meaningful PFS advantage of aumolertinib over osimertinib in treatment\u2010na\u00efve EGFR\u2010mutant NSCLC, particularly for exon 19del\u2010driven and co\u2010mutation\u2010negative disease, while maintaining equivalent safety. These findings provide valuable real\u2010world evidence supporting the use of aumolertinib as a first\u2010line therapy, contributing to the optimization of treatment selection and AE management. While these subgroup\u2010specific results offer hypothesis\u2010generating insights into potential biomarkers for therapeutic individualization, these preliminary findings require further validation in larger, prospective cohorts.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70617","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:50:01Z","timestamp":1785912601000},"page":"2575-2584","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aumolertinib Versus Osimertinib as First\u2010Line Treatment for\n                    <scp>EGFR<\/scp>\n                    \u2010Mutant Non\u2010Small Cell Lung Cancer: A\u00a0Retrospective Real\u2010World Multicenter Study"],"prefix":"10.1002","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2431-4431","authenticated-orcid":false,"given":"Jinxia","family":"Wang","sequence":"first","affiliation":[{"name":"The First Clinical Medical College of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Qi","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4464-9285","authenticated-orcid":false,"given":"Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology The Second Hospital of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Oncology Gansu Provincial Cancer Hospital  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery The First Hospital of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Department of Radiotherapy Gansu Provincial People's Hospital  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Oncology Scientific Group of the Central Medical Department Jiangsu Hansoh, Pharmaceutical Group co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Hospital of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Hospital of Lanzhou University  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251358871"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.028"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1063716"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0731-8"},{"key":"e_1_2_12_6_1","first-page":"10","article-title":"T790M and Acquired Resistance of EGFR TKI: A Literature Review of Clinical Reports","volume":"3","author":"Ma C.","year":"2011","journal-title":"Journal of Thoracic Disease"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-649"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11956-w"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00839-w"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03577-y"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1331138"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100271"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.11.001"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646577"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-754"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.11.014"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2362613"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.02.064"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55050"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0305-6"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70617","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70617","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:32:32Z","timestamp":1790076752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,15]]}},"alternative-id":["10.1002\/ijc.70617"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70617","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2025-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}